Central Retinal Vein Occlusion, Depression, Retinal Vein Occlusion, Venous Retinal Branch Occlusion
Conditions
Keywords
Retinal vein occlusion, Ranibizumab, Lucentis, Depression
Brief summary
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.
Interventions
0.5 mg, administered intravitreally every 4 weeks
Sponsors
Genentech, Inc.
Retina Associates of Cleveland, Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Ability to provide written informed consent and comply with study assessments for the full duration of the study * Evidence of central retinal vein occlusion, defined as documented retinal hemorrhage into all four quadrants with dilated veins, or branch retinal vein occlusion, as documented on clinical exam * Age 18 years or over * Central macular edema on clinical exam as well as imaging with a central thickness of ≥ 250 microns * Visual acuity ranging from 20/8000 to 20/40 * Media clarity and patient cooperation sufficient to allow adequate testing utilizing OCT and FA * No previous treatment that might compromise or confound assessment of the study outcomes * Ability to speak and read English
Exclusion criteria
* Acute illness or cognitive or other impairment that, in the opinion of the investigator, would interfere with study requirements * Concurrent ocular conditions likely to significantly compromise vision and contribute the macular compromise * History of grid/focal laser in the study eye * History of vitreal surgery * Previous treatment with triamcinolone acetonide in either eye * Previous use of bevacizumab, pegaptanib, or ranibizumab in either eye * Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders * History of cerebrovascular accident within 1 year prior to Day 0 * Inability to comply with study or follow-up procedures * Any cognitive defect as a result of mental disease, previous injury, or disease process that may interfere with interpretation of study results * Visual acuity better than 20/40 * Pregnancy (positive pregnancy test) or lactation * Inadequate contraception in premenopausal women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures are changes in the VFQ-25, GHQ-12, and PHQ-9 survey scores from baseline through 24 weeks. | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures are change in macular edema measured by OCT and estimated by central retinal thickening and correlations between change in visual acuity, depression, and retinal findings such as neovascularization, rubeosis, and perfusion. | 24 weeks |
Countries
United States
Outcome results
None listed